SEC Comment Letter for Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334) (VRCA) — Nov 29, 2022

Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334)
Date: Nov. 29, 2022 · CIK: 0001660334 · Accession: 0000000000-22-012873

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38529

Date

November 29, 2022

Author

Terry Kohler

Form

UPLOAD

Company

Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334)

Letter

United States securities and exchange commission logo November 29, 2022 Terry Kohler Chief Financial Officer Verrica Pharmaceuticals Inc. 44 West Gay Street, Suite 400 West Chester, PA 19380 Re:Verrica Pharmaceuticals Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 2, 2022 File No. 001-38529 Dear Terry Kohler: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
November 29, 2022
Terry Kohler
Chief Financial Officer
Verrica Pharmaceuticals Inc.
44 West Gay Street, Suite 400
West Chester, PA 19380
Re:Verrica Pharmaceuticals Inc.
Form 10-K for the Fiscal Year Ended December 31, 2021
Filed March 2, 2022
File No. 001-38529
Dear Terry Kohler:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io